Progressive nuclear translocation of somatostatin analogs.

Autor:	Hornick CA; Department of Physiology, The Stanley S. Scott Cancer Center, New Orleans, Louisiana, USA., Anthony CT, Hughey S, Gebhardt BM, Espenan GD, Woltering EA
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2000 Jul; Vol. 41 (7), pp. 1256-63.
Abstrakt:	Unlabelled: Optimal cancer radiotherapy using Auger electron emitters requires selective localization of radionuclides in close proximity to tumor DNA. Methods: Intracellular trafficking of (125)I-Tyr1-somatostatin-14 somatotropin-release inhibiting factor (SRIF) and 2 of its analogs, (125)I-WOC 4a and (111)In-pentetreotide, was studied in human neuroblastoma cells. Results: After 24-h incubation, SRIF was degraded or recycled, whereas its protease-resistant analogs progressively accumulated in nuclear fractions. (111)In-pentetreotide binding to DNA increased over time in somatostatin receptor-positive cells but not in somatostatin receptor-negative cells. Conclusion: These in vitro studies show that prolonged exposure to radiolabeled SRIF analogs significantly increases their cellular internalization, nuclear translocation, and DNA binding. Clinically, infusion of radiolabeled somatostatin analogs may enhance tumor uptake and retention and provide more effective in situ radiotherapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu